32.43
price down icon7.69%   -2.70
after-market After Hours: 32.43
loading
Ultragenyx Pharmaceutical Inc stock is traded at $32.43, with a volume of 879.48K. It is down -7.69% in the last 24 hours and down -21.09% over the past month.
See More
Previous Close:
$35.13
Open:
$34.32
24h Volume:
879.48K
Relative Volume:
1.12
Market Cap:
$3.18B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-5.0124
EPS:
-6.47
Net Cash Flow:
$-439.53M
1W Performance:
-14.25%
1M Performance:
-21.09%
6M Performance:
-39.71%
1Y Performance:
-31.12%
1-Day Range:
Value
$32.07
$34.79
1-Week Range:
Value
$32.07
$36.98
52-Week Range:
Value
$32.07
$60.37

Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile

Name
Name
Ultragenyx Pharmaceutical Inc
Name
Phone
415-483-8800
Name
Address
60 LEVERONI COURT, NOVATO, CA
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
RARE's Discussions on Twitter

Compare RARE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RARE
Ultragenyx Pharmaceutical Inc
32.43 3.18B 522.75M -558.99M -439.53M -6.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-06-24 Upgrade Goldman Neutral → Buy
Apr-22-24 Initiated RBC Capital Mkts Outperform
Dec-08-23 Initiated Wells Fargo Overweight
Jun-14-23 Resumed Credit Suisse Outperform
Jun-06-23 Upgrade Evercore ISI In-line → Outperform
Apr-26-23 Initiated Cantor Fitzgerald Overweight
Jan-18-23 Resumed Canaccord Genuity Buy
Dec-30-22 Resumed H.C. Wainwright Buy
Nov-03-22 Upgrade Robert W. Baird Neutral → Outperform
Oct-13-22 Upgrade Guggenheim Neutral → Buy
Aug-01-22 Downgrade Evercore ISI Outperform → In-line
Mar-16-22 Upgrade Credit Suisse Neutral → Outperform
Feb-11-22 Upgrade JP Morgan Neutral → Overweight
Sep-30-21 Initiated H.C. Wainwright Buy
Aug-19-21 Initiated UBS Sell
Jul-15-21 Initiated Guggenheim Neutral
Jun-29-21 Upgrade BofA Securities Neutral → Buy
Jun-04-21 Resumed Robert W. Baird Neutral
May-06-21 Upgrade Citigroup Neutral → Buy
May-06-21 Upgrade Evercore ISI In-line → Outperform
Apr-26-21 Resumed Credit Suisse Neutral
Mar-02-21 Resumed Stifel Buy
Feb-12-21 Downgrade JP Morgan Overweight → Neutral
Dec-07-20 Downgrade Wedbush Outperform → Neutral
Nov-24-20 Resumed Evercore ISI In-line
Nov-12-20 Downgrade BofA Securities Buy → Neutral
Aug-02-19 Resumed Wedbush Outperform
Mar-27-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Feb-22-19 Resumed Raymond James Outperform
Jan-02-19 Downgrade Raymond James Outperform → Mkt Perform
Nov-08-18 Upgrade Citigroup Sell → Neutral
Sep-10-18 Initiated Morgan Stanley Equal-Weight
Jun-21-18 Downgrade Credit Suisse Outperform → Neutral
May-11-18 Upgrade Barclays Equal Weight → Overweight
May-10-18 Initiated Goldman Neutral
Apr-18-18 Upgrade SunTrust Hold → Buy
Mar-22-18 Resumed Piper Jaffray Overweight
Feb-21-18 Reiterated Stifel Buy
Jan-22-18 Upgrade Evercore ISI In-line → Outperform
Jan-18-18 Initiated Credit Suisse Outperform
Dec-05-17 Reiterated Barclays Equal Weight
Dec-04-17 Upgrade Jefferies Hold → Buy
Sep-14-17 Upgrade Wedbush Neutral → Outperform
View All

Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News

pulisher
04:27 AM

Ultragenyx stock hits 52-week low at $33.37 amid market challenges - Investing.com India

04:27 AM
pulisher
Apr 02, 2025

How another firm's FDA approval could mean a big win for Denali TherapeuticsSan Francisco Business Times - The Business Journals

Apr 02, 2025
pulisher
Apr 02, 2025

Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals

Apr 02, 2025
pulisher
Apr 02, 2025

Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week LowShould You Sell? - MarketBeat

Apr 02, 2025
pulisher
Mar 30, 2025

11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey

Mar 30, 2025
pulisher
Mar 29, 2025

Why Ultragenyx Pharmaceutical (RARE) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey

Mar 29, 2025
pulisher
Mar 27, 2025

Ultragenyx Stays On JPMorgan's Focus List As Analyst Highlights Strong Long-Term Positioning - Benzinga

Mar 27, 2025
pulisher
Mar 27, 2025

Ultragenyx price target raised to $117 from $104 at JPMorgan - TipRanks

Mar 27, 2025
pulisher
Mar 26, 2025

Ultragenyx stock hits 52-week low at $36.99 amid market challenges - Investing.com Australia

Mar 26, 2025
pulisher
Mar 26, 2025

Ultragenyx stock hits 52-week low at $36.99 amid market challenges By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 24, 2025

Ultragenyx CEO Emil Kakkis: ‘Our Future Is In Our Hands’ - insights.citeline.com

Mar 24, 2025
pulisher
Mar 24, 2025

Can UX111 Script History As The First FDA-Approved Treatment For Sanfilippo Syndrome Type A? - RTTNews

Mar 24, 2025
pulisher
Mar 19, 2025

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

Ultragenyx Strengthens Team with Strategic RSU Grants Worth Millions - StockTitan

Mar 19, 2025
pulisher
Mar 18, 2025

Ultragenyx price target lowered to $115 from $140 at Piper Sandler - Yahoo Finance

Mar 18, 2025
pulisher
Mar 17, 2025

Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Demystifying Ultragenyx Pharmaceutical: Insights From 10 Analyst Reviews - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

Piper Sandler cuts Ultragenyx stock target to $115; keeps overweight - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Opinion: Angelman Syndrome Race Heats Up Among Ionis, Ultragenyx and Neuren - BioSpace

Mar 17, 2025
pulisher
Mar 12, 2025

Trending Report on X-linked Hypophosphatemia Market 2025-2032 - openPR

Mar 12, 2025
pulisher
Mar 11, 2025

Have Insiders Sold Ultragenyx Pharmaceutical Shares Recently? - Simply Wall St

Mar 11, 2025
pulisher
Mar 10, 2025

Ultragenyx pharmaceutical CFO sells $72,114 in common stock By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Ultragenyx pharmaceutical CFO sells $72,114 in common stock - Investing.com India

Mar 10, 2025
pulisher
Mar 07, 2025

Ultragenyx Pharmaceutical, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

Ultragenyx Pharmaceutical: Strong Buy Rating Backed by Growth Potential and Robust Pipeline - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

FDA grants priority review to gene therapy for Sanfilippo type A - Sanfilippo News

Mar 06, 2025
pulisher
Mar 05, 2025

Ultragenyx Pharmaceutical Inc Reports Q4 2024 Revenue of $165 Mi - GuruFocus.com

Mar 05, 2025
pulisher
Mar 05, 2025

Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 05, 2025

Ultragenyx’s chief accounting officer sells $40,710 in stock By Investing.com - Investing.com Australia

Mar 05, 2025
pulisher
Mar 05, 2025

Ultragenyx pharmaceutical executive sells $607,881 in stock - Investing.com Australia

Mar 05, 2025
pulisher
Mar 04, 2025

Ultragenyx pharmaceutical CBO Kassberg sells $253k in stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx EVP Eric Crombez sells $376,584 in stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx EVP Eric Crombez sells $376,584 in stock By Investing.com - Investing.com Australia

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx pharmaceutical EVP sells $635,836 in stock - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx pharmaceutical EVP sells $635,836 in stock By Investing.com - Investing.com Canada

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx CEO Emil Kakkis sells $4.15 million in stock By Investing.com - Investing.com UK

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx’s chief accounting officer sells $40,710 in stock - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.

Mar 04, 2025
pulisher
Mar 04, 2025

Ultragenyx EVP Karah Parschauer sells $128,223 in stock By Investing.com - Investing.com Canada

Mar 04, 2025
pulisher
Mar 03, 2025

Ultragenyx Loses Bid To Toss Suit Over Henrietta Lacks' Cells - Law360

Mar 03, 2025
pulisher
Mar 03, 2025

Ultragenyx EVP Karah Parschauer sells $128,223 in stock - Investing.com India

Mar 03, 2025
pulisher
Mar 01, 2025

(RARE) Technical Pivots with Risk Controls - Stock Traders Daily

Mar 01, 2025
pulisher
Mar 01, 2025

Y Intercept Hong Kong Ltd Raises Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat

Mar 01, 2025

Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):